Evidence map›Paper›PMID 36835136›Full record

ReviewInternational journal of molecular sciences2023

The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia.

Akiko Urabe, SungGi Chi, Yosuke Minami

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. The Epigenetic Landscape of Hemophilia.Current molecular medicine · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Akiko UrabeDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Chiba, Japan.
SungGi ChiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Chiba, Japan.ORCID 0000-0002-5725-7187
Yosuke MinamiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Chiba, Japan.
National Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypomethylating agents (HMAs) have been used for decades in the treatment of hematologic neoplasms, and now, have gathered attention again in terms of their combination with potent molecular-targeted agents such as a BCL-6 inhibitor venetoclax and an

Indexed as

DNA MethylationLeukemia, Myeloid, AcuteAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicDNAGenomicsHumansSulfonamidesTumor MicroenvironmentAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicDNASulfonamidesvenetoclaxacute myeloid leukemiaCD47hypomethylating agentsPD-1

Identifiers

PMID36835136
PMCPMC9961620
OpenAlexW4320492926

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.